A Phase 2 interventional study of bimagrumab and placebo in Sarcopenia, sponsored by Novartis Pharmaceuticals. Completed at 58 sites in 13 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.
Among the 187 studies in Sarcopenia with a site in United States, this one is the 8th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2014, is one of 20 in phase 2, and was the 60th registered.
1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
Kennesaw State University · Sites in United States
Ages 65–85 · Healthy volunteers
Health Discovery Labs · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 3 · Phase 4 5
First in 1995; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 60 across 856 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 146 interventional studies, 70 across the 40 observational. Of the 126 that completed or were terminated, 43 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
16 of the studies in Sarcopenia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT06722508University of California, DavisExercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06628349Texas A&M UniversityPrandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein | 2026-12 |
| NCT03998202Wake Forest University Health SciencesMyopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 187 studies in Sarcopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BYM338 70 mg intravenous infusion
Drug: bimagrumab
BYM338 210 mg intravenous infusion
Drug: bimagrumab
BYM338 700 mg intravenous infusion
Drug: bimagrumab
Placebo intravenous infusion
Other: placebo
Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Also known as: BYM338
Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
Also known as: 5% dextrose
Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25
Change from Baseline in total Short Physical Performance Battery (SPPB) Score to week 25; SPPB is a series of six activities involving three domains of physical function - balance, usual walking speed and rising from a chair , is commonly used globally to assess and quantify (score 0-12) lower extremity function and has been shown to predict future adverse health events. A decline of one or more points in the SPPB total score is predictive of a decrease in lower extremity function and future adverse clinical outcomes in older adults, including falls, hospitalizations, institutionalization, incident disability and death
Time frame: Baseline, week 25
Change From Baseline at Week 25 in the 6 Minute Walk Test (6MWT) Distance
Change from Baseline at Week 25 in the 6 minute walk test (6MWT) distance to measure improvement in physical function
Time frame: Baseline, week 25
Change From Baseline to Week 25 in Usual Gait Speed (GS) Over 4 Meters
Change from Baseline to Week 25 in usual Gait speed (GS) over 4 meters Gait speed in this study was assessed as part of the SPPB, over a 4 meter distance of a 6 meter course. This test assessed a person's usual walking speed, which was defined as the speed a person normally walks from one place to another without urgency (e.g., walking down a hallway).
Time frame: baseline, week 25
Percentage Change From Baseline to Week 25 on Appendicular Skeletal Muscle Index (ASMI) Measured by Dual Energy X-ray Absorptiometry (DXA)
Change from Baseline to Week 25 on appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) Appendicular skeletal muscle index (ASMI) is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m\^2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
Time frame: baseline, week 25
Percentage Change From Baseline to Week 25 on Total Lean Body Mass Measured by Dual Energy X-ray Absorptiometry (DXA)
Change from Baseline to Week 25 on Total lean body mass and appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.
Time frame: baseline, week 25
A total of 220 patients were randomized to receive six doses of either BYM338 70 mg, BYM338 210 mg, BYM338 700 mg or the placebo. However, only 217 patients were enrolled and dosed with BYM338 or placebo due to the withdrawal of three patients who did not meet the inclusion/exclusion criteria prior to receiving the first dose.
| Milestone | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Started | 19 | 18 | 113 | 67 |
| Completed | 17 | 12 | 95 | 64 |
| Not completed | 2 | 6 | 18 | 3 |
| Withdrew: Adverse event | 1 | 0 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 3 | 2 | 1 |
| Withdrew: Patient/guardian decision | 1 | 2 | 9 | 1 |
Change from Baseline in total Short Physical Performance Battery (SPPB) Score to week 25; SPPB is a series of six activities involving three domains of physical function - balance, usual walking speed and rising from a chair , is commonly used globally to assess and quantify (score 0-12) lower extremity function and has been shown to predict future adverse health events. A decline of one or more points in the SPPB total score is predictive of a decrease in lower extremity function and future adverse clinical outcomes in older adults, including falls, hospitalizations, institutionalization, incident disability and death
| Score on a scale | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Baseline | 7.1 ± 2.12 | 7.3 ± 2.11 | 7.2 ± 1.63 | 7.3 ± 1.67 |
| Week 25 | 8.5 ± 2.48 | 8.7 ± 1.64 | 8.7 ± 2.12 | 8.4 ± 2.25 |
Change from Baseline at Week 25 in the 6 minute walk test (6MWT) distance to measure improvement in physical function
| meters | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Baseline | 293.30 ± 91.842 | 291.81 ± 82.527 | 294.30 ± 83.602 | 312.43 ± 93.924 |
| Week 25 | 304.98 ± 102.934 | 340.71 ± 72.911 | 315.32 ± 97.020 | 322.71 ± 103.865 |
Change from Baseline to Week 25 in usual Gait speed (GS) over 4 meters Gait speed in this study was assessed as part of the SPPB, over a 4 meter distance of a 6 meter course. This test assessed a person's usual walking speed, which was defined as the speed a person normally walks from one place to another without urgency (e.g., walking down a hallway).
| m/sec | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Baseline | 2.37 ± 0.684 | 2.72 ± 0.752 | 2.58 ± 0.624 | 2.70 ± 0.493 |
| Week 25 | 3.12 ± 0.857 | 3.60 ± 0.699 | 3.30 ± 0.902 | 3.23 ± 0.838 |
Change from Baseline to Week 25 on appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) Appendicular skeletal muscle index (ASMI) is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m\^2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
| Percent Change | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Baseline | 5.99 ± 0.886 | 5.87 ± 0.795 | 5.70 ± 0.823 | 5.55 ± 0.753 |
| Week 25 | 6.04 ± 0.947 | 6.42 ± 0.849 | 6.10 ± 0.836 | 5.60 ± 0.717 |
Change from Baseline to Week 25 on Total lean body mass and appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.
| Percent Change | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Baseline | 37.44 ± 8.507 | 35.84 ± 7.300 | 35.39 ± 8.891 | 33.65 ± 6.890 |
| Week 25 | 38.26 ± 8.660 | 39.52 ± 8.343 | 37.86 ± 9.064 | 33.95 ± 6.921 |
Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 25 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338 70 mg | 0/19 (0%) | 0/19 (0%) | 12/19 (63.2%) |
| BYM338 210 mg | 0/18 (0%) | 3/18 (16.7%) | 13/18 (72.2%) |
| BYM338 700 mg | 2/113 (1.8%) | 14/113 (12.4%) | 94/113 (83.2%) |
| Placebo | 0/67 (0%) | 5/67 (7.5%) | 41/67 (61.2%) |
| Event | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/19 | 1/18 | 0/113 | 0/67 |
| Spinal fractureInjury, poisoning and procedural complications | 0/19 | 1/18 | 0/113 | 0/67 |
| Blood alkaline phosphatase increasedInvestigations | 0/19 | 1/18 | 0/113 | 0/67 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/19 | 1/18 | 0/113 | 0/67 |
| Colitis ulcerativeGastrointestinal disorders | 0/19 | 0/18 | 0/113 | 1/67 |
| Anaphylactic reactionImmune system disorders | 0/19 | 0/18 | 0/113 | 1/67 |
| InfluenzaInfections and infestations | 0/19 | 0/18 | 0/113 | 1/67 |
| Back painMusculoskeletal and connective tissue disorders | 0/19 | 0/18 | 0/113 | 1/67 |
| Neck painMusculoskeletal and connective tissue disorders | 0/19 | 0/18 | 0/113 | 1/67 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 0/18 | 0/113 | 1/67 |
| Event | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 2/19 | 3/18 | 28/113 | 24/67 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/19 | 5/18 | 37/113 | 10/67 |
| DiarrhoeaGastrointestinal disorders | 1/19 | 3/18 | 22/113 | 2/67 |
| AcneSkin and subcutaneous tissue disorders | 0/19 | 3/18 | 3/113 | 0/67 |
| NasopharyngitisInfections and infestations | 3/19 | 1/18 | 5/113 | 0/67 |
| Upper respiratory tract infectionInfections and infestations | 1/19 | 2/18 | 5/113 | 5/67 |
| Back painMusculoskeletal and connective tissue disorders | 1/19 | 2/18 | 5/113 | 3/67 |
| BradycardiaCardiac disorders | 2/19 | 0/18 | 3/113 | 0/67 |
| VertigoEar and labyrinth disorders | 2/19 | 0/18 | 1/113 | 2/67 |
| ContusionInjury, poisoning and procedural complications | 0/19 | 1/18 | 5/113 | 7/67 |
| Age, Continuous(years) | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 79.3 ± 5.89 | 78.0 ± 6.38 | 79.5 ± 5.46 | 78.3 ± 5.03 | 79.0 ± 5.45 |
| Sex: Female, Male(Participants) | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 9 | 8 | 66 | 43 | 126 |
| Male | 10 | 10 | 47 | 24 | 91 |
| Race (NIH/OMB)(Participants) | BYM338 70 mg | BYM338 210 mg | BYM338 700 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 5 | 3 | 17 | 11 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 3 | 0 | 0 | 1 | 4 |
| White | 11 | 14 | 93 | 54 | 172 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2014 to primary completion in Jun 2018, 42 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab